Survival of the fittest or best adapted: HLA-dependent tumor development

  • Giuseppe V. Masucci | giuseppe.masucci@ki.se Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Emilia Andersson Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Lisa Villabona Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Hildur Helgadottir Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Kjell Bergfeldt Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Switzerland.
  • Federica Cavallo Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
  • Guido Forni Molecular Biotechnology Center, Via Nizza 52, 10126 Torino, Italy, Italy.
  • Soldano Ferrone University of Pittsburgh Cancer Institute, Departments of Surgery, Immunology and Pathology, School of Medicine, Pittsburgh, PA, USA, United States Minor Outlying Islands.
  • Aniruddha Choudhury Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.
  • Barbara Seliger Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, Halle/Saale, Germany, Germany.
  • Rolf Kiessling Department of Oncology-Pathology The Karolinska Hospital SE-171 77 Stockholm, Sweden, Sweden.

Abstract

The major histocompatibility complex (MHC) comprises a set of genes that are critical to immunity and surveillance against neoplastic transformation. There is increasing evidence that the MHC antigens not only regulate antitumor immune responses in experimental animal models but directly correlate with survival and prognosis of patients with diverse types of cancers. MHC antigens may in the future function as potential biomarkers for prognosis and allow selection of cancer patients for intensive therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2010-05-27
Info
Issue
Section
Reviews
Keywords:
Cancer, HLA, Ancestral Haplotypes, DNA, mRNA
Statistics
  • Abstract views: 1384

  • PDF: 452
  • HTML: 3317
How to Cite
Masucci, G. V., Andersson, E., Villabona, L., Helgadottir, H., Bergfeldt, K., Cavallo, F., Forni, G., Ferrone, S., Choudhury, A., Seliger, B., & Kiessling, R. (2010). Survival of the fittest or best adapted: HLA-dependent tumor development. Journal of Nucleic Acids Investigation, 1(1), e9. https://doi.org/10.4081/jnai.2010.1654